DeutschNewstral
Article
jdsupra.com on 2020-02-06 00:41
Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA
Related news
- FDA And FTC To Scrutinize Biologics Competitionjdsupra.com
- FTC and FDA Announce Plans to Combat Anticompetitive Practices in the "Biologic Marketplace"jdsupra.com
- DOJ/FTC Issue Warning to Healthcare Industry Regarding Anticompetitive Conduct Against Employees During the COVID-19 Crisisjdsupra.com
- Colombia: New anticompetitive conduct for government contractsjdsupra.com
- FTC Comment on FDA Guidancejdsupra.com
- Medical Device Claims Sent to FTC, FDAjdsupra.com
- FTC v. Qualcomm: Hypercompetitive or Anticompetitive?jdsupra.com
- FDA Issues Real-World Evidence Framework for Drugs and Biologicsjdsupra.com
- 2019 FDA Enforcement Review: Drugs, Biologics, Devices, and Dietary Supplementsjdsupra.com
- January 2019 IP Update - Restricting Keyword Advertising Can be Anticompetitive, holds the FTCjdsupra.com
- FTC v. Qualcomm Decision—Qualcomm Enjoined From Anticompetitive Practices, Creating Standard-Essential-Patent Licensing Uncertaintyjdsupra.com
- AGs’ COVID-19-Related Resources | Nursing Homes Investigated | Anticompetitive Conduct In Labor Marketsjdsupra.com
- FDA and FTC Issue Warnings Concerning e-Cigarette Marketingjdsupra.com
- Promotional Regulation and Enforcement: FDA, FTC and State Interactionsjdsupra.com
- FDA and FTC Announce Collaboration to Support Biosimilars Marketjdsupra.com
- FDA, FTC Warn CBD Maker Over Product Claimsjdsupra.com
- FTC backs FDA guidance intended to curtail citizen petition “shenanigans”jdsupra.com
- Antitrust Enforcers On Alert For Anticompetitive Conduct Targeting Health Care And Frontline Workersjdsupra.com
- FDA and FTC Announce Collaboration to Promote Biosimilar Competition; FDA Issues Draft Promotional Guidancejdsupra.com
- THE LATEST: FTC to Look Closely at Competition between Biologics and Biosimilars and Patent Protection Strategies of Branded Manufacturersjdsupra.com